39.27
-0.29 (-0.73%)
| Penutupan Terdahulu | 39.56 |
| Buka | 39.71 |
| Jumlah Dagangan | 270,118 |
| Purata Dagangan (3B) | 506,685 |
| Modal Pasaran | 1,952,386,176 |
| Harga / Jualan (P/S) | 3.58 |
| Harga / Buku (P/B) | 4.08 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Oct 2025 |
| Margin Keuntungan | -7.95% |
| Margin Operasi (TTM) | -4.82% |
| EPS Cair (TTM) | -0.810 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 13.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 17.03% |
| Nisbah Semasa (MRQ) | 4.11 |
| Aliran Tunai Operasi (OCF TTM) | 22.19 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.42 M |
| Pulangan Atas Aset (ROA TTM) | -3.70% |
| Pulangan Atas Ekuiti (ROE TTM) | -8.38% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Instruments & Supplies (US) | Menaik | Bercampur |
| Medical Instruments & Supplies (Global) | Menaik | Menurun | |
| Stok | AtriCure, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.00 |
|
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. |
|
| Sektor | Healthcare |
| Industri | Medical Instruments & Supplies |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.37% |
| % Dimiliki oleh Institusi | 103.60% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 64.00 (Canaccord Genuity, 62.97%) | Beli |
| Median | 56.00 (42.60%) | |
| Rendah | 48.00 (JP Morgan, 22.23%) | Beli |
| Purata | 56.00 (42.60%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 37.59 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| JP Morgan | 16 Dec 2025 | 48.00 (22.23%) | Beli | 41.08 |
| Canaccord Genuity | 30 Oct 2025 | 64.00 (62.97%) | Beli | 34.09 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 27 Jan 2026 | Pengumuman | AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results |
| 12 Jan 2026 | Pengumuman | AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026 |
| 17 Dec 2025 | Pengumuman | AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference |
| 11 Dec 2025 | Pengumuman | AtriCure Announces the First Patients Treated with Novel Dual Energy Platform |
| 18 Nov 2025 | Pengumuman | AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |